Psychedelics Are Racing Toward FDA Approval. For Addiction, the Evidence Is Still Mostly Stories.

Mark Guckel fought crack cocaine from high school onward, tried to stop more times than he could count, and says ayahuasca, psilocybin and ibogaine are what finally helped him quit. When he sat on a Harvard Law panel to talk about it, he warned people off his own story. “While psychedelics helped me to stop using substances, I’d like to reflect that these aren’t a cure,” he said. “They are catalysts. They’re sacraments, they’re medicines, they’re tools.”

Today, with the federal government sprinting psychedelics toward the pharmacy shelf, that is the most honest sentence anyone has said about them.

The fast track is for depression and PTSD. Nobody has proven these drugs for addiction, and the people selling the hope know it.

Guckel, now a recovery coach with a company that offers psychedelic-assisted recovery, has a stake in the answer, which is worth knowing and doesn’t make him wrong. What makes him credible is that he said “not a cure” out loud when it would have sold better to say the opposite.

The fast track is real, and it is not about you

The speed is not hype. In April, the FDA gave national priority review vouchers to Compass Pathways (psilocybin for depression that hasn’t responded to other treatment), the Usona Institute (psilocybin for major depression) and Transcend Therapeutics (methylone, an MDMA-like compound, for PTSD). A voucher is a place at the front of the line, not an approval. It followed an executive order, signed April 18, pushing the agency to speed psychedelic research.

Compass’s psilocybin hit the main goal it set in advance in two late-stage trials, according to Mark S. Gold, M.D., writing in Psychology Today on October 4, and the company says a rolling application is under review. Gold’s own caution is the part to underline: no psilocybin or LSD product is approved, company announcements are not FDA decisions, and progress in depression and anxiety “does not establish” that the same drug helps with a substance use disorder. Each drug needs its own proof for each condition.

Read that against who gets studied. Gold notes that trials often exclude people with psychosis, bipolar risk, or active substance use disorders. If you are the person this newsroom is written for, the trials that built the headlines were often designed to leave you out.

What the evidence for addiction actually is

Strip away the testimonials and the picture is thin. At that Harvard panel, Deborah Mash, a University of Miami neurologist who has studied ibogaine for addiction for more than thirty years, called it “a very powerful addiction interrupter,” and in the same breath said the evidence is largely anecdotal: “data are not the plural of anecdote.” Stories like her patient on methadone who reportedly had no withdrawal or cravings are case accounts, not trial results.

Then there is the problem inside the trials that do exist. Orsini and colleagues reviewed 112 randomized psychedelic trials in JAMA Psychiatry this year; only 33 even checked whether people could tell what they had been given. Where it was checked, studies of psilocybin, LSD and ayahuasca often found more than 90% of participants and raters could guess. You know why. A drug that rearranges your whole sense of reality is hard to mistake for a sugar pill, and when everyone knows who got the real thing, hope does some of the work the molecule is credited with. That doesn’t mean the drug does nothing. It means the size of the effect is unknown.

We have watched the field run into this wall once already. In August 2024 the FDA declined to approve MDMA-assisted therapy for PTSD and asked for another trial, a decision the drugmaker Lykos disputed. The industry had spent years assuming the case was made. Afterward, Science reported, other developers set out to avoid the same fate. The lesson they took was to build tighter trials for depression, anxiety and PTSD. The lesson for addiction is the same one, years behind: the careful trial has to be run before the promise is.

The lesson they took was to build tighter trials for depression, anxiety and PTSD.

The risk that has a body count

Ibogaine is the one most often pitched to people in withdrawal, and it carries the clearest danger. Harvard law professor Mason Marks put it bluntly at the panel: “Ibogaine has been linked to heart attacks and some deaths.” Gold adds the mechanism: ibogaine can disturb the heart’s rhythm in a way that can be fatal, and a September 29 JAMA Network Open survey of 1,964 U.S. adults found higher reported side-effect rates among people who had used ibogaine or 5-MeO-DMT. Gold stresses it was a survey, not a controlled safety study. The honest reading is that nobody knows the true rate, which is exactly why it is dangerous to treat it as a shortcut. Our earlier post on the FDA’s ibogaine trial safety-comment request has more.

There is also an implementation gate. Even if the FDA approves a psilocybin product, it would still have to clear drug scheduling, state law, and insurers before it reached a clinic near you. A fast review does not mean access next month. And Stephanie Tabashneck, the panel’s moderator and a Harvard law and neuroscience fellow, was clear that psychedelic therapy is not a replacement for medication like methadone in opioid use disorder.

What to do this week

If you work with people in recovery, add one question to intake or your next team meeting: has anyone on your caseload used, or been pitched, ibogaine or psilocybin for cravings? Ask it without a lecture, because people who feel judged stop telling you things. If someone is planning ibogaine anywhere, the practical safety move is to get a heart tracing (an ECG) and a full medication review before they go, and to tell them plainly what the heart risk is.

If you are the person who has been pitched, the thing that is still real tonight: the medicines with the strongest evidence for opioid and alcohol use disorder (buprenorphine, methadone, naltrexone) are available now, and nothing in the psychedelic pipeline replaces them. Our Find Treatment tool can show you who near you offers them.

Guckel’s word was tools. A tool does not do the work. Whatever is in the ceremony or the clinic, you are the one who goes home to the Tuesday afterward, and what we have seen carry people through that Tuesday is the unglamorous stuff: someone who answers the phone, a prescription that doesn’t lapse, a room where you can say the true thing.